Not Yet RecruitingPhase 2

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

33 participantsStarted 2026-04-06

Plain-language summary

This is a single-arm, exploratory clinical study.

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Neck ultrasound and contrast-enhanced chest/abdominal CT.
✓. Ultrasound-guided lymph node biopsy or PET/CT if clinical suspicion or neck ultrasound suggests cervical lymph node metastasis.
✓. Abdominal non-contrast and contrast-enhanced MRI or PET/CT to confirm diagnosis if CT suggests liver metastasis.
✓. Bone scan if necessary in case of systemic bone pain symptoms.
✓. Endoscopic ultrasound for accurate staging.

Pathological Complete Response, pCR

Timeframe: Periprocedural

NCT IDNCT07490002

SponsorChanghai Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-11-30

Xianbao Zhan